Study to Evaluate the Effect of Six Cycles of Treatment With a Combined Oral Contraceptive (EE 0.30 mg/DRSP 3 mg) on Quality of Life.

• Status: Completed
• Trial end date: 2004-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the effects on the quality of life and BMI of new contraceptives.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Drospirenone; Drospirenone and ethinyl estradiol combination; Ethinyl Estradiol

Criteria

Inclusion Criteria:

• Female requiring contraceptives.

• Aged 18 to 35 if a non-smoker, aged 18 to 30 if a smoker.

• Regular menstrual cycle (defined as duration of 28 +/- 5 days).

Exclusion Criteria:

• No Contraindication for OC use